藥物輸送的共同研究及授權契約:2019年～2025年

"藥物輸送領域的合作與授權協議" 提供了前所未有的途徑，讓我們能夠全面了解世界領先生物製藥公司達成的藥物輸送交易。

這份經過全面修訂和更新的報告詳細介紹了2019年至2025年的藥物輸送交易。

本報告詳細解讀並分析了企業達成藥物輸送交易的方式和原因。這些交易通常涉及多個環節，從合作研發開始，到成果商業化結束。

本報告涵蓋了合作、開發、研究和授權交易。

本報告包​​含自2019年以來宣布的1,246項藥物輸送交易的完整列表，其中包括交易各方披露的實際藥物輸送合作交易的在線交易記錄鏈接以及財務條款（如有）。此外，我們會盡可能記錄公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告第一章介紹了藥物遞送交易。

第一章是對報告的介紹。

第二章概述了自2019年以來的藥物遞送交易趨勢。

第三章概述了自2019年以來具有代表性的藥物遞送交易。交易按總價值列出。

第四章提供了藥物遞送交易中最活躍的25家公司的綜合列表，隨後進行了簡要摘要，並提供了公開的合約文件。

第五章對自2019年1月以來簽署和宣布的藥物遞送交易進行了全面深入的回顧，這些交易的合約文件均可公開查閱。

第六章全面深入地回顧了自2019年1月以來達成和宣布的藥物輸送合作交易。本章以特定的藥物傳輸技術類型進行組織。

報告還提供了大量圖表和數據，顯示了自2019年以來藥物輸送交易的趨勢和活動。

此外，報告還提供了一個全面的交易目錄，按公司A-Z、交易類型和治療目標進行整理。每個交易標題都透過網頁連結連結到線上交易記錄，並包含合約文件（如有），方便您隨時存取每個合約文件。

主要的優點

藥物輸送合作與授權協議為讀者提供以下主要優勢：

• 了解 2019 年及以後的交易趨勢
• 瀏覽藥物傳遞合作與授權協議
• 基準分析 - 確定交易的市場價值
• 財務條款 - 一次性付款、里程碑付款、特許權使用費
• 公司 A-Z、交易類型和治療領域排列的交易目錄
• 主要交易價值
• 最活躍的交易者
• 確定每筆交易的資產和交易條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款是否適合您的合作夥伴
• 節省數百小時的研究時間

調查範圍

• 藥物輸送合作與許可協議旨在深入了解藥物輸送全球領先生物製藥公司簽署的藥物輸送合作與許可協議包括：

藥物輸送合作與授權協議包括：

• 生物製藥產業的藥物輸送交易趨勢
• 涵蓋製藥和生物技術領域的藥物傳輸交易記錄目錄
• 主要藥物輸送交易
• 最活躍的藥物輸送許可交易商
• 藥物輸送合作與許可協議提供全面的交易記錄訪問，包括可用的合約文件。

分析協議有助於進行以下的盡職調查：

• 授予或選擇的具體權利是什麼？
• 合約實際上授予合作公司什麼？
• 授予了哪些獨家權利？
• 合約的付款結構是怎樣的？
• 如何審計銷售額和付款？
• 合約期限是多久？
• 合約的關鍵條款是如何定義的？
• 知識產權如何處理與歸屬？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和資訊揭露？
• 如何解決爭議？
• 合約在什麼情況下可以終止？
• 如果所有權發生變更會怎樣？
• 雙方約定了哪些再授權和分包條款？
• 公司堅持哪些標準條款？
• 哪些標準條款似乎因合作夥伴和交易類型而異？
• 公司在契約法方面主張哪些管轄權？

目錄

摘要整理

第1章 簡介

第2章 藥物輸送交易趨勢

• 簡介
• 多年的藥物輸送交易
• 最活躍的藥物輸送交易業者
• 藥物輸送交易，各交易類型
• 藥物輸送交易，各治療領域
• 藥物輸送交易，各業界
• 藥物輸送交易的交易條件
  • 藥物輸送交易的標題金額
  • 藥物輸送契約的預付款
  • 藥物輸送契約的里程金
  • 藥物輸送權利金費率

第3章 -主要藥物輸送交易

• 簡介
• 主要的藥物輸送交易，各金額

第4章 -最活躍的藥物輸送交易業者

• 簡介
• 最活躍的藥物輸送交易業者
• 最活躍的藥物輸送交易的企業簡介

第5章 -藥物輸送契約交易名錄

• 簡介
• 藥物輸送契約交易名錄

第6章 -各技術類型的藥物輸送交易

• 交易名錄
• 交易名錄- 藥物輸送交易，各企業
• 交易名錄- 藥物輸送交易，各交易類型
• 交易名錄- 藥物輸送交易，各治療領域
• 交易類型定義
• 關於調查公司
• 目前聯盟
• 目前契約
• 最近的報告標題

Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the drug delivery deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of drug delivery deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1246 drug delivery deals announced since 2019 including financial terms where available including links to online deal records of actual drug delivery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of drug delivery dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in drug delivery dealmaking since 2019.

Chapter 3 provides an overview of the leading drug delivery deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in drug delivery dealmaking with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of drug delivery deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since Jan 2019. The chapter is organized by specific drug delivery technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in drug delivery deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Drug Delivery Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse drug delivery collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Drug Delivery Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of drug delivery trends and structure of deals entered into by leading biopharma companies worldwide.

Drug Delivery Collaboration and Licensing Deals includes:

• Trends in drug delivery dealmaking in the biopharma industry
• Directory of drug delivery deal records covering pharmaceutical and biotechnology
• The leading drug delivery deals by value
• Most active drug delivery licensing dealmakers
• Drug Delivery Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

• 2.1. Introduction
• 2.2. Drug delivery deals over the years
• 2.3. Most active drug delivery dealmakers
• 2.4. Drug delivery deals by deal type
• 2.5. Drug delivery deals by therapy area
• 2.6. Drug delivery deals by industry sector
• 2.7. Deal terms for drug delivery deals
  • 2.7.1 Drug delivery deals headline values
  • 2.7.2 Drug delivery deal upfront payments
  • 2.7.3 Drug delivery deal milestone payments
  • 2.7.4 Drug delivery royalty rates

Chapter 3 - Leading drug delivery deals

• 3.1. Introduction
• 3.2. Top drug delivery deals by value

Chapter 4 - Most active drug delivery dealmakers

• 4.1. Introduction
• 4.2. Most active drug delivery dealmakers
• 4.3. Most active drug delivery deals company profiles

Chapter 5 - Drug delivery contracts dealmaking directory

• 5.1. Introduction
• 5.2. Drug delivery contracts dealmaking directory

Chapter 6 - Drug delivery dealmaking by technology type

• Deal directory
• Deal directory - Drug delivery deals by company A-Z
• Deal directory - Drug delivery deals by deal type
• Deal directory - Drug delivery deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Drug delivery deals since 2019
• Figure 2: Active drug delivery dealmaking activity - 2019 - 2025
• Figure 3: Drug delivery deals by deal type since 2019
• Figure 4: Drug delivery deals by therapy area since 2019
• Figure 5: Drug delivery deals by industry sector since 2019
• Figure 6: Drug delivery deals with a headline value
• Figure 7: Drug delivery deals with an upfront value
• Figure 8: Drug delivery deals with a milestone value
• Figure 9: Drug delivery deals with a royalty rate value
• Figure 10: Top drug delivery deals by value since 2019
• Figure 11: Most active drug delivery dealmakers 2019 - 2025
• Figure 12: Drug delivery deals by technology type since 2019